MedTrace Logo

Influence of Hyaluronic Acid on Bacillus Calmette-Guérin Local Side Effects

NCT02207608 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2015-05-28

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate a possible role of intravesical Hyaluronic Acid in reducing local toxicity of Bacillus Calmette Guerin (BCG) used to treat bladder urothelial cell carcinoma.

Conditions

  • Poisoning by BCG Vaccine

Interventions

DRUG

Hyaluronic Acid

Add hyaluronic acid to BCG Treatment

DRUG

BCG (Immucist®)

Usual BCG treatment

Sponsors & Collaborators

  • University of Rome Tor Vergata

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2012-08-31
Completion
2012-08-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02207608 on ClinicalTrials.gov